Welcome to our dedicated page for Xortx Therapeutics SEC filings (Ticker: XRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XORTX Therapeutics Inc. (XRTX) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. XORTX files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These filings furnish investors with information on financial performance, clinical and regulatory progress, securities offerings, and material corporate developments related to the company’s gout and kidney disease programs.
Recent Form 6-K submissions have included condensed interim consolidated financial statements, management discussion and analysis, and officer certifications, as well as press releases describing registered direct offerings, private placements, Nasdaq minimum bid price notifications, and the binding term sheet to acquire the VB4-P5 renal anti-fibrotic program from Vectus Biosystems Limited. Certain 6-K exhibits, such as legal opinions on the validity of securities, are incorporated by reference into XORTX’s shelf registration statement on Form F-3 (File No. 333-269429).
Through this page, users can review key filing types relevant to XORTX’s sector, including 6-K reports detailing clinical and regulatory updates for the XRx-026 gout program and related XORLO™ formulation, as well as financing structures involving common shares, pre-funded warrants, and agent warrants. The filings also document the company’s responses to Nasdaq listing requirements and its use of at-the-market and registered offerings to fund development of gout, ADPKD, acute kidney injury, and diabetic nephropathy programs.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in clear language. Real-time updates from EDGAR, along with structured access to XORTX’s 6-K reports and other registered offerings, help investors quickly understand how regulatory events, financings, and clinical disclosures affect the company’s xanthine oxidase–targeted pipeline.
XORTX Therapeutics Inc. filed a Form 6-K. The filing incorporates Exhibits 99.2 and 99.3 by reference into the company’s Registration Statement on Form F-3 (File No. 333-269429), adding legal opinions regarding the legality of securities being registered from Dentons Canada LLP and Troutman Pepper Locke LLP.
The exhibit index also lists a press release dated October 29, 2025 (Exhibit 99.1). The report is signed by President and Chief Executive Officer Allen Davidoff on October 31, 2025. This is an administrative update linking legal opinions to the existing F-3 shelf.
XORTX Therapeutics Inc. filed a Form 6-K furnishing transaction-related exhibits and incorporating them by reference into its Form F-3 registration statement (File No. 333-269429), as amended and supplemented.
The exhibits include a press release dated October 21, 2025, a Placement Agency Agreement with D. Boral Capital LLC, a form of Securities Purchase Agreement, a form of Lock-Up Agreement, and a form of Pre-Funded Common Share Purchase Warrant. The report was signed by President and CEO Allen Davidoff on October 22, 2025.
XORTX Therapeutics Inc. launched a registered direct offering to an institutional accredited investor, registering 572,470 common shares at $0.63 each, 1,177,530 pre-funded warrants at $0.62999 each with a $0.00001 exercise price, and 1,177,530 common shares underlying those warrants. The pre-funded warrants are immediately exercisable.
The fee table shows an aggregate offering price of $1,102,488, placement agent fees of $77,175, and proceeds before expenses of $1,025,313. The company estimates net proceeds of approximately $0.8 million for working capital and general corporate purposes. A beneficial ownership cap limits exercises above 4.99% (or, at the purchaser’s election at closing, 9.99%).
XRTX trades on the TSXV and Nasdaq. The company has applied to list the Shares and the Pre-Funded Warrant Shares on the TSXV and notified Nasdaq; TSXV approval is required. D. Boral Capital LLC is acting as exclusive placement agent on a best efforts basis. Delivery is expected on or about October 23, 2025, subject to customary conditions and TSXV approvals.
FAQ
What is the current stock price of Xortx Therapeutics (XRTX)?
What is the market cap of Xortx Therapeutics (XRTX)?
